Kidney cancer is usually not treated with chemotherapy or radiation after surgery because it is not sensitive to either radiation or chemotherapy, and can be treated with bioimmunotherapy after surgery.
Kidney cancer is a relatively common urological malignancy. Chemotherapy is usually not required after surgery because kidney cancer is not sensitive to either chemotherapy or radiotherapy, and bioimmunotherapy, such as interleukin and interferon, is usually administered first to prevent metastasis and recurrence of the cancer.
The need for follow-up therapy after cancer surgery requires a comprehensive analysis based on the patient’s specific situation, and in most cases follow-up therapy is needed to prevent recurrence and metastasis. Patients with advanced kidney cancer can be treated with targeted therapies, and the commonly used targeted therapies are sunitinib and sorafenib.
Patients with kidney cancer may have some symptoms in the early stage, such as hematuria, kidney mass and pain in the kidney area, so once patients find these abnormalities, they need to go to regular hospitals to improve the relevant examination and early treatment, which has a key impact on the healing of kidney cancer.